The evolving role of capecitabine in breast cancer

Clinical Breast Cancer

Volumn 4, Issue SUPPL. 1, 2003, Pages

  O'Shaughnessy, Joyce A ^a  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

Author keywords

5 fluorouracil; Angiognesis; Anthracyclines; Combination therapy; Taxanes

Indexed keywords

ANGIOGENIC FACTOR; ANTHRACYCLINE; ANTHRACYCLINE DERIVATIVE; BEVACIZUMAB; CAPECITABINE; CARBAMIC ACID DERIVATIVE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; METHOTREXATE; MONOCLONAL ANTIBODY; NAVELBINE; PACLITAXEL; RECOMBINANT ANTIBODY; TAMOXIFEN; TAXANE DERIVATIVE; THYMIDINE PHOSPHORYLASE; TRASTUZUMAB; VASCULOTROPIN;

AGE; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; BREAST METASTASIS; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; CROSS RESISTANCE; DIARRHEA; DRUG ACTIVATION; DRUG EFFICACY; DRUG INDICATION; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SCREENING; DRUG SELECTIVITY; DRUG TOLERABILITY; ENZYME ACTIVITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; GENDER; HAND FOOT SYNDROME; HIGH RISK PATIENT; HUMAN; LYMPH NODE; MONOTHERAPY; NEUROTOXICITY; PREOPERATIVE TREATMENT; PREVALENCE; PROTEIN EXPRESSION; PSORIASIS; REVIEW; UNITED STATES;

EID: 0038783141     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2003.s.011     Document Type: Review

References (33)

1. Jemal A, Thomas A, Murray T, et al. Cancer statistics, 2003. CA Cancer J Clin 2003; 53:5-26.
2. Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34:1274-1281.
3. Schuller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000; 45:291-297.
4. O'Reilly S, Moiseyenko V, Talbot D, et al. A randomized phase II study of Xeloda (capecitabine) versus paclitaxel in breast cancer patients failing previous anthracycline therapy. Proc Am Soc Clin Oncol 1998; 17:163 (Abstract #627).
5. O'Shaughnessy J, Blum J, Moiseyenko V, et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 2001; 12:1247-1254.
6. Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 17:485-493.
7. Reichardt P, von Minckwitz G, Luck H, et al. Capecitabine: the new standard in metastatic breast cancer failing anthracycline and taxane-containing chemotherapy? Mature results of a large multicenter phase II trial. Eur J Cancer 2001; 37:191 (Abstract #699).
8. Blum JL, Dieras V, Lo Russo PM, et al. Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 2001; 92:1759-1768.
9. Sawada N, Ishikawa T, Fukase Y, et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 1998; 4:1013-1019.
10. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20:2812-2823.
11. Burstein HJ, Manola J, Younger J, et al. Docetaxel administered on weekly basis for metastatic breast cancer. J Clin Oncol 2000; 18:1212-1219.
12. Hainsworth JD, Burris HA, Yardley DA, et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 2001; 19:3500-3505.
13. Tonkin K, Scarfe AG, Koski S, et al. Preliminary. results of a phase I/II study of weekly docetaxel (Taxotere) combined with intermittent capecitabine (Xeloda) for patients with anthracycline pretreated metastatic breast cancer. Proc Am Soc Clin Oncol 2001; 20:67b (Abstract #2016).
14. Nadella P, Shapiro C, Otterson GA et al. Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies. J Clin Oncol 2002; 20:2616-2623.
15. Scarfs AG, Bodnar D, Tonkin K, et al. Interim results of a phase II study of weekly docetaxel (Taxotere) combined with intermittent capecitabine (Xeloda) for patients with anthracycline pre-treated metastatic breast cancer. Proc Am Soc Clin Oncol 2002; 21:43b (Abstract #1984).
16. Villalona-Calero MA, Blum JL, Jones SE, et al. A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients. Ann Oncol 2001; 12:605-614.
17. Meza L, Amin B, Horsey M, et al. A phase II study of capecitabine in combination with paclitaxel as first or second line therapy in patients with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2001; 21:70b (Abstract #2029).
18. Bangemann N, Kuhle A, Ebert A, et al. Capecitabine combined with trastuzumab in the therapy of intensively pretreated HER-2 overexpressing metastatic breast cancer (MBC). Ann Oncol 2000; 11:143 (Abstract #653P).
19. Fumoleau P, Delgado F, Delozier T, et al. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 1993; 11:1245-1252.
20. Gasparini G, Caffo O, Barni S, et al. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study. J Clin Oncol 1994; 12:2094-2101.
21. Ghosn M, Farhat F, Kattan J, et al. Vinorelbine (Navelbine) IV and capecitabine as front line chemotherapy in metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2002; 21:42b (Abstract #1978).
22. Ahn J, Kim S, Lee J, et al. Phase II study of a combination chemotherapy of capecitabine and vinorelbine in metastatic breast cancer with previous exposure to anthracycline and taxane: preliminary results. Proc Am Soc Clin Oncol 2002; 21:55b (Abstract #2030).
23. Slamon D, Clark G, Wong S, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 1987; 235:177-182.
24. Vogel C, Cobleigh M, Tripathy D, et al. First-line, single agent Herceptin® (trastuzumab) in metastatic breast cancer: a preliminary report. Eur J Cancer 2001; 37(suppl 1):25-29.
25. Fujimoto-Ouchi K, Sekiguchi F, Tanaka Y. Antitumor activity of combinations of anti-HER-2 antibody trastuzumab and oral fluoropyrimidines capecitabine/5′dFUrd in human breast cancer models. Cancer Chemother Pharmacol 2002; 49:211-216.
26. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994; 79:185-188.
27. Cobleigh M, Miller K, Langmuir V, et al. Phase II dose escalation trial of Avastin (bevacizumab) in women with previously treated metastatic breast cancer. Breast Cancer Res Treat 2001; 69:301 (Abstract #520).
28. Miller K, Rugo H, Cobleigh M, et al. Phase III trial of capecitabine (Xeloda) plus bevacizumab (Avastin) versus capecitabine alone in women with metastatic breast cancer (MBC) previously treated with an anthracycline and a taxane. Breast Cancer Res Treat 2002; 76:S37 (Abstract #36).
29. Trimble EL, Carter CL, Cain D, et al. Representation of older patients in cancer treatment trials. Cancer 1994; 74:2208-2214.
30. Crawford J, Dale D, Lyman G, et al. Suboptimal dosing in adjuvant breast cancer chemotherapy: evidence from a nationwide survey. Breast Cancer Res Treat 2000; 64:66 (Abstract #241).
31. Livingston R. Current trials with capecitabine in the adjuvant therapy of breast cancer, American Society of Clinical Oncology Meeting; May 17, 2002; Orlando, Fla.
32. Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001; 30:96-102.
33. Project NSABP The effect on primary tumor response of adding sequential Taxotere to Andriamycin and cyclophosphamide: preliminary results from NSABP proocol B-27. Breast Cancer Res Treat 2001; 69:210 (Abstract #5).